Life Science Nation Newsletter  | January 19,  2017  |  Issue 197

  The LSN Story   |   Investor Platform   |   Company Platform   |   RESI Conference   |   Fundraising Consulting
Life Science Investor Mandates (Jan. 12  - Jan. 18)
Invests in Oncology, Cardiovascular & Psychiatry Therapeutics
Seeks Healthcare IT Deals
Dedicates New Fund to Early Stage Medtech
Invests in Clinical-stage Drugs and Medical Technology
In This Issue
News
Nature BioEntrepreneur Features LSN: Aligning Needs
LSN Services
Click to see investors that are a fit for your product and stage of development

Click here if you are a service provider and want to see a list of funded life science companies that are a fit for you

Click here if you want to receive free, targeted early stage dealflow for your life science investment firm

LSN Book

LSN Videos
By Natasha Eldridge, Marketing Manager - RESI Conference Series, LSN

On April 4, 2017, The Redefining Early Stage Investments (RESI) Conference will be back to Toronto's MaRS Discovery District, the home of notable life science organizations including JLABS@Toronto, the Ontario Institute for Cancer Research, Synaptive Medical, and LEAGUE. RESI on MaRS will bring together fundraising CEOs and early stage investors from around the globe, providing the opportunity for dialogue and relationship building, with the goal of eventual capital allocations...

By Dennis Ford, Founder & CEO, LSN

RESI @ JPM has generated feedback from a wide swath of attendees thus far. What LSN has heard has been two quite distinctive words: "Crazy good." An interesting mantra, and it's right on.

The overriding response was that the RESI conference is not stale (same old talking heads for decades) or burdened with a sterile-like quality of private white meeting rooms. RESI is not the "quiet car," and most certainly is not projecting a low energy library-like atmosphere.

On the contrary, when you step into the beehive of RESI and into its palatable energy and buzzing noise, you know it's different. It's not only for the elite phase III and commercialization cadre that play in the later stage life science arena.

The RESI conference series is the Wild West of the life science arena, with preclinical and early stage players not looking to be catered to with pomp and circumstance - actually just the opposite. The game is afoot - let's engage in the hunt for assets! Send forth the hounds, blow the trumpets, let's make some noise...

By Lucy Parkinson, Director of Research, LSN

As RESI attracts increasing media attention, BioWorld have provided some highlights and analysis on RESI's content. This roundup focuses on two of RESI's investor panels: Biotech Angels and Tales From The Road. Between these two sessions, RESI attendees caught a high-level view inside an early stage life science deal from both sides. On one side of the table, angel investors explore how they hunt for deals and work with startups after investment...